Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (5708)	11/25/1998 4:45:00 PM
From: Joe E.	Read Replies (1) of 6136

Here is a summary piece from the daily CDC news briefs: << "Antiretroviral Therapy During Asymptomatic HIV Infection Saves Immune Function" Reuters Health Information Services (11/24/98) The Swiss HIV Cohort Study has found that the administration of highly active antiretroviral therapy (HAART) to asymptomatic HIV-positive patients early in the course of infection can help preserve pre-therapy levels of immune function. The researchers determined that treatment with zidovudine, lamivudine, and ritonavir in 15 asymptomatic patients resulted in a reduction of HIV RNA levels, memory CD8+/CD45RO+ cells, and activated CD4+/HLA-DR+, CD8+/HLA-DR+, and CD8+/CD38+ T cells. There was also an increase in the number of naive CD4+/CD45RA+ and memory CD4+/CD45RO+ T cells. The authors, who report their findings in the Nov. 12 issue of AIDS, assert that the data support the early administration of HAART.>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next